Literature DB >> 26666918

Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.

Zaineb A F Albayati1, Manjula Sunkara2, Suzannah M Schmidt-Malan3, Melissa J Karau3, Andrew J Morris2, James M Steckelberg4, Robin Patel5, Philip J Breen1, Mark S Smeltzer6, K Grant Taylor7, Kevyn E Merten8, William M Pierce9, Peter A Crooks10.   

Abstract

We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26666918      PMCID： PMC4776008          DOI： 10.1128/AAC.01609-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.

Authors:  Tammy S Lundstrom; Jack D Sobel
Journal:  Infect Dis Clin North Am       Date:  2004-09       Impact factor: 5.982

2.  Penetration of vancomycin in uninfected sternal bone.

Authors:  L Massias; C Dubois; P de Lentdecker; O Brodaty; M Fischler; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

3.  Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres.

Authors:  Erdal Cevher; Zafer Orhan; Lütfiye Mülazimoğlu; Demet Sensoy; Murat Alper; Ayca Yildiz; Yildiz Ozsoy
Journal:  Int J Pharm       Date:  2006-04-19       Impact factor: 5.875

4.  3-O-phosphate ester conjugates of 17-β-O-{1-[2-carboxy-(2-hydroxy-4-methoxy-3-carboxamido)anilido]ethyl}1,3,5(10)-estratriene as novel bone-targeting agents.

Authors:  Shama Nasim; Ashish P Vartak; William M Pierce; K Grant Taylor; Ned Smith; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-10-13       Impact factor: 2.823

5.  Surgical treatment of osteomyelitis.

Authors:  George Cierny
Journal:  Plast Reconstr Surg       Date:  2011-01       Impact factor: 4.730

Review 6.  Antibiotic treatment of gram-positive bone and joint infections.

Authors:  Elizabeth S R Darley; Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2004-04-29       Impact factor: 5.790

Review 7.  Waves of resistance: Staphylococcus aureus in the antibiotic era.

Authors:  Henry F Chambers; Frank R Deleo
Journal:  Nat Rev Microbiol       Date:  2009-09       Impact factor: 60.633

8.  Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent.

Authors:  Jason R Neale; Natali B Richter; Kevyn E Merten; K Grant Taylor; Sujan Singh; Leonard C Waite; Nicole K Emery; Ned B Smith; Jian Cai; William M Pierce
Journal:  Bioorg Med Chem Lett       Date:  2008-12-24       Impact factor: 2.823

9.  Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis.

Authors:  Karen E Beenken; Laura Bradney; William Bellamy; Robert A Skinner; Sandra G McLaren; M Johannes Gruenwald; Horace J Spencer; James K Smith; Warren O Haggard; Mark S Smeltzer
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

10.  Effects of bead size and polymerization in PMMA bone cement on vancomycin release.

Authors:  K Shinsako; Y Okui; Y Matsuda; J Kunimasa; M Otsuka
Journal:  Biomed Mater Eng       Date:  2008       Impact factor: 1.300
View more
  7 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

2.  Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Qun Yan; Kerryl E Greenwood-Quaintance; Jayawant Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Developments in Glycopeptide Antibiotics.

Authors:  Mark A T Blaskovich; Karl A Hansford; Mark S Butler; ZhiGuang Jia; Alan E Mark; Matthew A Cooper
Journal:  ACS Infect Dis       Date:  2018-02-19       Impact factor: 5.084

4.  Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone.

Authors:  Zaineb A F Albayati; Narsimha R Penthala; Shobanbabu Bommagani; Ginell R Post; Mark S Smeltzer; Peter A Crooks
Journal:  Toxicol Rep       Date:  2021-02-09

Review 5.  Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.

Authors:  Emma van Groesen; Paolo Innocenti; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-07-27       Impact factor: 5.578

Review 6.  Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.

Authors:  Nhan Dai Thien Tram; Pui Lai Rachel Ee
Journal:  Antibiotics (Basel)       Date:  2017-07-04

Review 7.  New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Roman Manetsch; George A O'Doherty; James E Kirby
Journal:  Transl Res       Date:  2020-03-02       Impact factor: 7.012
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.